Cargando…
Considerations for payers in managing hormone receptor-positive advanced breast cancer
Breast cancer (BC) is the second most common cause of death in women. In 2010, the direct cost associated with BC care in the US was $16.5 billion, the highest among all cancers. By the year 2020, at the current rates of incidence and survival, the cost is projected to increase to approximately $20...
Autores principales: | Chitre, Mona, Reimers, Kristen M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4096457/ https://www.ncbi.nlm.nih.gov/pubmed/25031542 http://dx.doi.org/10.2147/CEOR.S57214 |
Ejemplares similares
-
Treatment Considerations for the Management of Patients With Hormone Receptor–Positive Metastatic Breast Cancer
por: Visovsky, Constance
Publicado: (2014) -
Combination Therapies in Advanced, Hormone Receptor–Positive Breast Cancer
por: Olson, Emily
Publicado: (2018) -
Treating Elderly Patients With Hormone Receptor–Positive Advanced Breast Cancer
por: Riseberg, David
Publicado: (2015) -
Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers
por: Migliaccio, Ilenia, et al.
Publicado: (2015) -
Recent advances in the treatment of hormone receptor-positive/human epidermal growth factor 2-positive advanced breast cancer
por: Lv, Huimin, et al.
Publicado: (2021)